Conceptos falsos y estrategias de mitigación | 18 ABR 16

Prescripción de opioides para el dolor crónico

Los médicos tienen dudas acerca de cuáles analgésicos opioides deben prescribirse para el dolor crónico, en qué momento y de qué manera.
INDICE:  1. Página 1 | 2. Referencias

1. Institute of Medicine. Relieving pain in America: a blueprint for transforming prevention, care, education and research. Washington, DC: National Academies Press, 2011.
2. Johannes CB, Le TK, Zhou X, Johnston JA, Dworkin RH. The prevalence of chronic pain in United States adults: results of an Internet-based survey. J Pain 2010; 11:1230-9.
3. Centers for Disease Control and Prevention. FastStats. Therapeutic drug use. 2014 (http://www .cdc .gov/ nchs/ fastats/ drug -use-therapeutic .htm).
4. Levy B, Paulozzi L, Mack KA, Jones CM. Trends in opioid analgesic-prescribing rates by specialty, U.S., 2007-2012. Am J Prev Med 2015; 49: 409-13.
5. National Institute on Drug Abuse. The latest prescription trends for controlled prescription drugs. 2015 (http://www .drugabuse .gov/ news-events/ meetings -events/ 2015/ 09/ latest-prescription-trends -controlled-prescription-drugs).
6. Volkow ND, McLellan TA, Cotto JH, Karithanom M, Weiss SR. Characteristics of opioid prescriptions in 2009. JAMA 2011; 305: 1299-301.
7. Boudreau D, Von Korff M, Rutter CM, et al. Trends in long-term opioid therapy for chronic non-cancer pain. Pharmacoepidemiol Drug Saf 2009; 18: 1166-75.
8. Chou R, Deyo R, Devine B, Hansen R, Sullivan S, Jarvik J. The effectiveness and risks of long-term opioid treatment of chronic pain: Evidence Report/Technology Assessment. Rockville, MD: Agency for Healthcare Research and Quality, 2014. No. 218 (AHRQ publication no. 14-E005-EF).
9. Results from the 2013 National Survey on Drug Use and Health:  summary of national findings. NSDUH series H-48. Rockville, MD: Substance Abuse and Mental Health Services Administration, 2014. HHS publication no. (SMA) 14-4863.
10. Compton WM, Boyle M, Wargo E. Prescription opioid abuse: problems and responses. Prev Med 2015; 80: 5-9.
11. Shei A, Rice JB, Kirson NY, et al. Sources of prescription opioids among diagnosed opioid abusers. Curr Med Res Opin 2015; 31: 779-84.
12. Keller CE, Ashrafioun L, Neumann AM, Van Klein J, Fox CH, Blondell RD. Practices, perceptions, and concerns of primary care physicians about opioid dependence associated with the treatment of chronic pain. Subst Abus 2012; 33: 103-13.
13. Hagemeier NE, Gray JA, Pack RP. Prescription drug abuse: a comparison of prescriber and pharmacist perspectives. Subst Use Misuse 2013; 48: 761-8.
14. Nuckols TK, Anderson L, Popescu I, et al. Opioid prescribing: a systematic review and critical appraisal of guidelines for chronic pain. Ann Intern Med 2014;160: 38-47.
15. American Pain Society, American Academy of Pain Medicine Opioids Guidelines Panel. Guideline for the use of chronic opioid therapy in chronic noncancer pain:evidence review (http://americanpainsociety .org/ uploads/ education/ guidelines/ chronic -opioid-therapy-cncp .pdf).
16. The Management of Opioid Therapy for Chronic Pain Working Group. VA/DoD clinical practice guideline for management of opioid therapy for chronic pain. Washington, DC: Department of Veterans Affairs, Department of Defense, 2010.
17. Dowell D, Haegerich TM, Chou R. CDC guideline for prescribing opioides for chronic pain — United States, 2016. MMWR Recomm Rep 2016; 65(No. RR-1):1-49.
18. Connock M, Juarez-Garcia A, Jowett S, et al. Methadone and buprenorphine for the management of opioid dependence: a systematic review and economic evaluation. Health Technol Assess 2007; 11: 1-171.
19. Kreek MJ. Methadone-related opioid agonist pharmacotherapy for heroin addiction: history, recent molecular and neurochemical research and  future in mainstream medicine. Ann N Y Acad Sci 2000; 909: 186-216.
20. Nutt DJ. Considerations on the role of buprenorphine in recovery from heroin addiction from a UK perspective. J Psychopharmacol 2015; 29: 43-9.
21. Akil H, Watson SJ, Young E, Lewis ME, Khachaturian H, Walker JM. Endogenous opioids: biology and function. Annu Rev Neurosci 1984; 7: 223-55.
22. Pattinson KT. Opioids and the control of respiration. Br J Anaesth 2008; 100: 747-58.
23. Miguez G, Laborda MA, Miller RR. Classical conditioning and pain: conditioned analgesia and hyperalgesia. Acta Psychol (Amst) 2014; 145: 10-20.
24. Ewan EE, Martin TJ. Analgesics as reinforcers with chronic pain: evidence from operant studies. Neurosci Lett 2013; 557 Pt A: 60-4.
25. Butler SF, Black RA, Cassidy TA, Dailey TM, Budman SH. Abuse risks and routes of administration of different prescription opioid compounds and formulations. Harm Reduct J 2011; 8: 29.
26. Department of Health and Human Services. Guidance for industry: abusedeterrent opioids: evaluation and labeling. April 2015 (http://www .fda .gov/ downloads/Drugs/ GuidanceComplianceRegulatory Information/ Guidances/ UCM334743 .pdf).
27. Mastropietro DJ, Omidian H. Abusedeterrent formulations: part 2: commercial products and proprietary technologies. Expert Opin Pharmacother 2015; 16: 305-23.
28. Raffa RB, Pergolizzi JV Jr. Opioid formulations designed to resist/deter abuse. Drugs 2010; 70: 1657-75.
29. Williams JT, Christie MJ, Manzoni O. Cellular and synaptic adaptations mediating opioid dependence. Physiol Rev 2001;81: 299-343.
30. Buntin-Mushock C, Phillip L, Moriyama K, Palmer PP. Age-dependent opioid escalation in chronic pain patients. Anesth Analg 2005; 100: 1740-5.
31. Eder H, Jagsch R, Kraigher D, Primorac A, Ebner N, Fischer G. Comparative study of the effectiveness of slow-release morphine and methadone for opioid maintenance therapy. Addiction 2005; 100:1101-9.
32. Kornetsky C, Bain G. Morphine: singledose tolerance. Science 1968; 162: 1011-2.
33. Hill R, Lyndon A, Withey S, et al. Ethanol reversal of tolerance to the respiratory depressant effects of morphine. Neuropsychopharmacology 2016; 41: 762-73.
34. Ling GS, Paul D, Simantov R, Pasternak GW. Differential development of acute tolerance to analgesia, respiratory depression, gastrointestinal transit and hormone release in a morphine infusion model. Life Sci 1989; 45: 1627-36.
35. Argoff C, Turk D, Benzon H. Major opioids and chronic opioid therapy. Philadelphia: Mosby Elsevier, 2008.
36. Wax P, Ruha A. Withdrawal syndromes: opioid withdrawal. In: Irwin RS, Rippe JM, eds. Irwin & Rippe’s intensive care medicine. Philadelphia: Lippincott Williams & Wilkins, 2003.
37. Arout CA, Edens E, Petrakis IL, Sofuoglu M. Targeting opioid-induced hyperalgesia in clinical treatment: neurobiological considerations. CNS Drugs 2015;
29: 465-86.
38. Kim SH, Stoicea N, Soghomonyan S, Bergese SD. Intraoperative use of remifentanil and opioid induced hyperalgesia/acute opioid tolerance: systematic review. Front Pharmacol 2014; 5: 108.
39. Chen L, Sein M, Vo T, et al. Clinical interpretation of opioid tolerance versus opioid-induced hyperalgesia. J Opioid Manag 2014; 10: 383-93.
40. Lee M, Silverman SM, Hansen H, Patel VB, Manchikanti L. A comprehensive review of opioid-induced hyperalgesia. Pain Physician 2011; 14: 145-61.
41. Lev R, Petro S, Lee A, et al. Methadone related deaths compared to all prescription related deaths. Forensic Sci Int 2015; 257: 347-52.
42. Paulozzi LJ. Prescription drug overdoses: a review. J Safety Res 2012; 43: 283-9.
43. Paulozzi LJ, Zhang K, Jones CM, Mack KA. Risk of adverse health outcomes with increasing duration and regularity of opioid therapy. J Am Board Fam Med 2014; 27: 329-38.
44. Edlund MJ, Martin BC, Russo JE, DeVries A, Braden JB, Sullivan MD. The role of opioid prescription in incident opioid abuse and dependence among individuals with chronic noncancer pain: the role of opioid prescription. Clin J Pain 2014; 30: 557-64.
45. Miller M, Barber CW, Leatherman S, et al. Prescription opioid duration of action and the risk of unintentional overdose among patients receiving opioid therapy. JAMA Intern Med 2015; 175: 608-15.
46. Pergolizzi J, Böger RH, Budd K, et al. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone). Pain Pract 2008; 8: 287-313.
47. Cheatle MD, Webster LR. Opioid therapy and sleep disorders: risks and mitigation strategies. Pain Med 2015; 16: Suppl 1:S22-6.
48. Beaudoin FL, Merchant RC, Janicki A, McKaig DM, Babu KM. Preventing iatrogenic overdose: a review of in-emergency department opioid-related adverse drug events and medication errors. Ann Emerg Med 2015; 65: 423-31.
49. Boscarino JA, Rukstalis M, Hoffman SN, et al. Risk factors for drug dependence among out-patients on opioid therapy in a large US health-care system. Addiction 2010; 105: 1776-82.
50. Alcohol involvement in opioid pain reliever and benzodiazepine drug abuserelated emergency department visits and
drug-related deaths—United States, 2010. MMWR Morb Mortal Wkly Rep 2014; 63:881-5.
51. Hasegawa K, Brown DF, Tsugawa Y, Camargo CA Jr. Epidemiology of emergency department visits for opioid overdose: a population-based study. Mayo Clin Proc 2014; 89: 462-71.
52. Chambers RA, Taylor JR, Potenza MN. Developmental neurocircuitry of motivation in adolescence: a critical period of addiction vulnerability. Am J Psychiatry 2003; 160: 1041-52.
53. Callop N, Cassel DK. Snoring and sleep disordered breathing. In: Lee-Chiong T Jr, Sateia M, Carskadon M, eds. Sleep medicine. Philadelphia: Hanley & Belfus, 2002.
54. Bosilkovska M, Walder B, Besson M, Daali Y, Desmeules J. Analgesics in patients with hepatic impairment: pharmacology and clinical implications. Drugs 2012; 72: 1645-69.
55. Verbeeck RK. Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction. Eur J Clin Pharmacol 2008; 64: 1147-61.
56. Mercadante S, Arcuri E. Opioids and renal function. J Pain 2004; 5: 2-19.
57. Christie MJ. Cellular neuroadaptations to chronic opioids: tolerance, withdrawal and addiction. Br J Pharmacol 2008; 154:384-96.
58. Kalivas PW, Volkow ND. The neural basis of addiction: a pathology of motivation and choice. Am J Psychiatry 2005; 162: 1403-13.
59. Volkow ND, Morales M. The brain on drugs: from reward to addiction. Cell 2015; 162: 712-25.
60. Uhl GR, Drgo T. Genetic contributions to individual differences in vulnerability to addiction and abilities to quit. In: Verster JC, Brady K, Galanter M, Conrad P, eds. Drug abuse and addiction in medical illness: causes, consequences and treatment. New York: Springer, 2012: 95-105.
61. Hall FS, Drgonova J, Jain S, Uhl GR. Implications of genome wide association studies for addiction: are our a priori assumptions all wrong? Pharmacol Ther 2013; 140: 267-79.
62. Mistry CJ, Bawor M, Desai D, Marsh DC, Samaan Z. Genetics of opioid dependence: a review of the genetic contribution to opioid dependence. Curr Psychiatry Rev 2014; 10: 156-67.
63. Tsuang MT, Lyons MJ, Meyer JM, et al. Co-occurrence of abuse of different drugs in men: the role of drug-specific and shared vulnerabilities. Arch Gen Psychiatry 1998; 55: 967-72.
64. Xian H, Chantarujikapong SI, Scherrer JF, et al. Genetic and environmental influences on posttraumatic stress disorder, alcohol and drug dependence in twin pairs. Drug Alcohol Depend 2000; 61: 95-102.
65. Public policy statement on rapid and ultra rapid opioid detoxification. Chevy Chase, MD: American Society of Addiction Medicine, 2005.
66. Seaman SR, Brettle RP, Gore SM. Mortality from overdose among injecting drug users recently released from prison: database linkage study. BMJ 1998; 316:426-8.
67. Wines JD Jr, Saitz R, Horton NJ, Lloyd-Travaglini C, Samet JH. Overdose after detoxification: a prospective study. Drug Alcohol Depend 2007; 89: 161-9.
68. Common elements in guidelines for prescribing opioids for chronic pain. Atlanta: Centers for Disease Control and Prevention, 2015.
69. McCabe SE, Cranford JA, Boyd CJ, Teter CJ. Motives, diversion and routes of administration associated with nonmedical use of prescription opioids. Addict Behav 2007; 32: 562-75.
70. Chou R, Fanciullo GJ, Fine PG, et al. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain 2009; 10: 113-30.
71. Gwira Baumblatt JA, Wiedeman C, Dunn JR, Schaffner W, Paulozzi LJ, Jones TF. High-risk use by patients prescribed opioids for pain and its role in overdose deaths. JAMA Intern Med 2014; 174: 796-801.
72. Manchikanti L, Helm S II, Fellows B, et al. Opioid epidemic in the United States. Pain Physician 2012; 15: Suppl: ES9-38.
73. McDonald DC, Carlson KE. Estimating the prevalence of opioid diversion by “doctor shoppers” in the United States. PLoS One 2013; 8(7): e69241.
74. Chou R, Turner JA, Devine EB, et al. The effectiveness and risks of long-term opioid therapy for chronic pain: a systematic review for a National Institutes of Health Pathways to Prevention Workshop. Ann Intern Med 2015; 162: 276-86.
75. Smith PC, Schmidt SM, Allensworth- Davies D, Saitz R. A single-question screening test for drug use in primary care. Arch Intern Med 2010; 170: 1155-60.
76. Executive summary. Pathways to prevention workshop: the role of opioids in the treatment of chronic pain. Bethesda, MD: National Institutes of Health, September 2014 (https:/ / prevention .nih .gov/ docs/programs/ p2p/ ODPPainPanelStatement Final_10-02-14 .pdf) .
77. Jones T, Moore T, Levy JL, et al. A comparison of various risk screening methods in predicting discharge from opioid treatment. Clin J Pain 2012; 28: 93-100.
78. Wang J, Christo PJ. The influence of prescription monitoring programs on chronic pain management. Pain Physician 2009; 12: 507-15.
79. Delcher C, Wagenaar AC, Goldberger BA, Cook RL, Maldonado-Molina MM. Abrupt decline in oxycodone-caused mortality after implementation of Florida’s Prescription Drug Monitoring Program. Drug Alcohol Depend 2015; 150: 63-8.
80. Paulozzi LJ, Kilbourne EM, Desai HA. Prescription drug monitoring programs and death rates from drug overdose. Pain Med 2011; 12: 747-54.
81. Surratt HL, O’Grady C, Kurtz SP, et al. Reductions in prescription opioid diversion following recent legislative interventions in Florida. Pharmacoepi demiol Drug Saf 2014; 23: 314-20.
82. Deyo RA, Irvine JM, Hallvik SE, et al. Leading a horse to water: facilitating registration and use of a prescription drug monitoring program. Clin J Pain 2014 November 7 (Epub ahead of print).
83. Hildebran C, Cohen DJ, Irvine JM, et al. How clinicians use prescription drug monitoring programs: a qualitative inquiry. Pain Med 2014; 15: 1179-86.
84. Irvine JM, Hallvik SE, Hildebran C, Marino M, Beran T, Deyo RA. Who uses a prescription drug monitoring program and how? Insights from a statewide survey of Oregon clinicians. J Pain 2014; 15:747-55.
85. Prescription Drug Monitoring Program Training and Technical Assistance Center. State profiles reports. Waltham, MA:Brandeis University (http://www .pdmpassist .org/ pdf/ Collection_Frequency .pdf).
86. Model Alcohol and Other Drug Abuse Policy and Planning Coordination Act. Charlottesville, VA: National Alliance for Model State Drug Laws (http://www.namsdl .org/ library/ ).
87. Perrone J, Nelson LS. Medication reconciliation for controlled substances —an “ideal” prescription-drug monitoring program. N Engl J Med 2012; 366: 2341-3.
88. Calcaterra S, Glanz J, Binswanger IA. National trends in pharmaceutical opioid related overdose deaths compared to other substance related overdose deaths:1999-2009. Drug Alcohol Depend 2013;131: 263-70.
89. Rudd RA, Aleshire N, Zibbell JE, Gladden RM. Increases in drug and opioid overdose deaths — United States, 2000–2014. MMWR Morb Mortal Wkly Rep 2016; 64: 1378-82.
90. Knowlton A, Weir BW, Hazzard F, et al. EMS runs for suspected opioid overdose: implications for surveillance and prevention. Prehosp Emerg Care 2013; 17:317-29.
91. Centers for Medicare and Medicaid Services.  Opioid morphine equivalent conversion factors (https:/ / www .cms .gov/Medicare/ Prescription-Drug-Coverage/PrescriptionDrugCovContra/ Downloads/Opioid-Morphine-EQ-Conversion-Factors -March-2015 .pdf).
92. Von Korff M, Saunders K, Thomas Ray G, et al. De facto long-term opioid therapy for noncancer pain. Clin J Pain 2008; 24: 521-7.
93. Hall AJ, Logan JE, Toblin RL, et al. Patterns of abuse among unintentional pharmaceutical overdose fatalities. JAMA 2008; 300: 2613-20.
94. Madadi P, Persaud N. Suicide by means of opioid overdose in patients with chronic pain. Curr Pain Headache Rep 2014; 18:460.
95. Cheatle MD. Depression, chronic pain, and suicide by overdose: on the edge. Pain Med 2011; 12: Suppl 2: S43-8.
96. Starrels JL, Wu B, Peyser D, et al. It made my life a little easier: primary care providers’ beliefs and attitudes about using opioid treatment agreements. J Opioid Manag 2014; 10: 95-102.
97. Opioid overdose prevention programs providing naloxone to laypersons — United States, 2014. MMWR Morb Mortal Wkly Rep 2015; 64: 631-5.
98. Hou YY, Cai YQ, Pan ZZ. Persistent pain maintains morphine-seeking behavior after morphine withdrawal through reduced MeCP2 repression of GluA1 in rat central amygdala. J Neurosci 2015; 35:3689-700.
99. Zhang Z, Tao W, Hou YY, Wang W, Lu YG, Pan ZZ. Persistent pain facilitates response to morphine reward by downregulation of central amygdala GABAergic function. Neuropsychopharmacology 2014;39: 2263-71.
100. Banta-Green CJ, Merrill JO, Doyle SR, Boudreau DM, Calsyn DA. Opioid use behaviors, mental health and pain — development of a typology of chronic pain
patients. Drug Alcohol Depend 2009; 104: 34-42.
101. Fishbain DA, Cole B, Lewis J, Rosomoff HL, Rosomoff RS. What percentage of chronic nonmalignant pain patients exposed to chronic opioid analgesic therapy develop abuse/addiction and/or aberrant drug-related behaviors? A structured evidence-based review. Pain Med 2008; 9:444-59.
102. Martell BA, O’Connor PG, Kerns RD, et al. Systematic review: opioid treatment for chronic back pain: prevalence, efficacy, and association with addiction. Ann Intern Med 2007; 146: 116-27.
103. Vowles KE, McEntee ML, Julnes PS, Frohe T, Ney JP, van der Goes DN. Rates of opioid misuse, abuse, and addiction in chronic pain: a systematic review and data synthesis. Pain 2015; 156: 569-76.
104. McLellan AT, Skipper GS, Campbell M, DuPont RL. Five year outcomes in a cohort study of physicians treated for substance use disorders in the United States. BMJ 2008; 337: a2038.
105. Weiss RD, Potter JS, Griffin ML, et al. Long-term outcomes from the National Drug Abuse Treatment Clinical Trials Network Prescription Opioid Addiction Treatment Study. Drug Alcohol Depend 2015; 150: 112-9.
106. Office of the Assistant Secretary for Planning and Evaluation. Opioid abuse in the U.S. and HHS actions to address opioid-drug related overdoses and eaths. Washington, DC: Department of Health and Human Services, March 26, 2015 (https://aspe .hhs .gov/ basic-report/ opioid -abuse-us-and-hhs-actions-address-opioid -drug-related-overdoses-and-deaths).
107. Sullivan MD, Edlund MJ, Fan MY, Devries A, Brennan Braden J, Martin BC. Trends in use of opioids for non-cancer pain conditions 2000-2005 in ommercial and Medicaid insurance plans: the TROUP study. Pain 2008; 138: 440-9.
108. Volkow ND, McLellan TA. Curtailing diversion and abuse of opioid analgesics without jeopardizing pain treatment. JAMA 2011; 305: 1346-7.
109. Williams AC, Eccleston C, Morley S. Psychological therapies for the management of chronic pain (excluding headache) in adults. Cochrane Database Syst Rev 2012; 11: CD007407.
110. Busch AJ, Barber KA, Overend TJ, Peloso PM, Schachter CL. Exercise for treating fibromyalgia syndrome. Cochrane Database Syst Rev 2007; 4: CD003786.



Para ver los comentarios de sus colegas o para expresar su opinión debe ingresar con su cuenta de IntraMed.

Términos y condiciones de uso | Todos los derechos reservados | Copyright 1997-2023